## YaleNewHaven**Health** Smilow Cancer Hospital

#### Vale CANCER CENTER A Comprehensive Cancer Center Designated by the National Cancer Institute

# **Grand Rounds**

### Tuesday, January 21, 12:00pm

Smilow Auditorium, 55 Park Street Join us in person for lunch Zoom Access

### **NEW ADVANCES IN PROSTATE CANCER IN 2025**

### William K. Oh, MD

Director of Precision Medicine; Service Line Medical Director of Smilow Cancer Hospital at Greenwich Hospital

#### Needs:

1. Prostate cancer remains the leading cause of cancer and second leading cause of cancer death in men in the US. There have been many new advances in the biology, screening, diagnostic workup and treatment of prostate cancer. Given the rapid changes, an overview of these advances will help clinicians and researchers to keep pace with prostate cancer.

#### **Objectives:**

- 1. Review trends in epidemiology and screening of prostate cancer.
- 2. Understand new treatments in advanced prostate cancer and how that will improve survival.
- 3. Review how precision medicine including genomics and AI are being used to individualize treatment of prostate cancer.





William K. Oh, MD, is Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital, as well as Service Line Medical Director of Smilow Cancer Hospital at Greenwich Hospital.

Dr. Oh is a genitourinary oncologist with decades of experience caring for patients with prostate cancer. Before his appointment at Yale, Dr. Oh served as the Chief Medical Officer and Executive Vice President of the Prostate Cancer Foundation, where he focused on barriers to the delivery of care for prostate cancer nationally.

For more than a decade, Dr. Oh was Chief of Hematology and Medical Oncology, Deputy Director of the NCI-designated Tisch Cancer Institute and the Ezra Greenspan, MD Professor of Clinical Cancer Therapeutics at Icahn School of Medicine at Mount Sinai. He began his professional career at Dana-Farber Cancer Institute and Harvard Medical School, including roles as Clinical Director of the Lank Center for Genitourinary Oncology and Director of the Gelb Center for Translational Medicine.

Dr. Oh completed his undergraduate degree at Yale University, received his medical degree from New York University School of Medicine, and did his internship and residency at Brigham and Women's Hospital before his clinical fellowship in medical oncology at Dana-Farber Cancer Institute.

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>w</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Oh- Novartis; Abbott; Cytogen; AstraZeneca; Pfizer; Archetype Therapeutics; Sema4/GeneDx; NtxBio; Sumitomo; VieCure; . It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control to a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.